My studies of cancer genomes have led to characterization of multiple pediatric and adult
tumor types, to development of methods that identify and characterize changes in genomic
heterogeneity, to
defining acquired resistance mechanisms to targeted therapies and to designing novel, personalized vaccines for individual patients.